한글목차

여보이(이필리무맙) 시장 규모는 최근 급성장하고 있습니다. 2025년 601만 달러에서 2026년에는 666만 달러에 이르고, CAGR 10.8%의 성장이 전망되고 있습니다. 지난 수년간의 성장에는 악성 흑색종 및 고형암 적응증 승인, CTLA-4 억제요법의 성공, 종양센터에서의 채택 확대, 진행성 암의 미충족 수요, 생존율 개선 등이 주요 요인으로 작용한 것으로 분석됩니다.

여보이(이필리무맙) 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 993만 달러에 이르고, CAGR은 10.5%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 면역치료제 파이프라인의 확대, 병용요법 증가, 암 발병률 증가, 종양학 분야에 대한 투자 확대, 면역 프로파일링 기술의 발전 등을 꼽을 수 있습니다. 주요 동향으로는 면역관문억제제의 성장, 병용 면역치료의 확대, 진행성 암 영역에서의 사용 증가, 병원 기반 면역종양학 치료, 장기적인 암 생존에 대한 집중 등이 예측됩니다.

향후 몇 년 동안 흑색종(악성 흑색종)의 발생률 증가가 여보이(이필리무맙) 시장의 성장을 견인할 것으로 예측됩니다. 흑색종은 피부의 색소인 멜라닌을 생성하는 세포인 '멜라닌 세포'에서 발생하는 피부암의 일종입니다. 증가 요인으로는 햇빛 노출 증가, 생활습관의 변화, 오존층 파괴로 인한 자외선 방사선 증가를 들 수 있습니다. 또한, 인식도 향상과 진단기술의 발전으로 더 많은 사례를 발견할 수 있게 된 것도 한 요인입니다. 이필리맙(Yervoy)은 CTLA-4 단백질을 표적으로 하여 면역체계가 암세포를 인식하고 공격하는 능력을 향상시켜 진행 단계에서도 생존율 향상과 지속적인 효과를 보이는 등 흑색종 환자들에게 뚜렷한 혜택을 제공합니다. 예를 들어, 2024년 1월 미국암협회가 발표한 자료에 따르면, 2024년 미국에서 새로 발생하는 흑색종 사례는 약 10만 640건으로 예상되며, 그 중 남성 5만 9,170건, 여성 4만 1,470건이 발생할 것으로 예측되고 있습니다. 협회는 또한 2024년 8,290명이 흑색종으로 사망할 것으로 추정하고 있으며, 그 중 남성 5,430명, 여성 2,860명이 사망할 것으로 예상하고 있습니다. 이 때문에 흑색종 발생률 증가는 이필리맙 시장의 성장을 뒷받침하고 있습니다.

여보이(이필리무맙) 시장의 주요 기업들은 치료 효과 향상과 다양한 암종에 대한 적응증 확대를 위해 옵디보(니볼루맙)와 여보이(이필리무맙)(이필리무맙) 병용요법 등 혁신적인 병용요법 개발에 집중하고 있습니다. 이 병용요법은 상호보완적인 면역 체크포인트 경로를 표적으로 하여 시너지 효과를 발휘하여 흑색종, 신세포암과 같은 암종에서 면역반응과 효능을 향상시킵니다. 예를 들어, 2024년 6월 미국 제약사 브리스톨마이어스스퀴브(Bristol-Myers Squibb)는 진행성 간세포암(HCC) 환자의 1차 치료제로 옵디보와 여보이 병용요법을 평가한 CheckMate-9DW 임상의 유망한 결과를 발표했습니다. 이번 임상에서 이중 면역항암요법은 렌바티닙 또는 소라페닙을 이용한 표준치료 대비 전체 생존기간을 유의미하게 개선하여 진행성 HCC 환자에서 통계적으로 유의미한 혜택을 보였습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 시장 규제 상황과 투자환경

제29장 경쟁 구도와 기업 개요

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 시장 잠재력이 높은 국가, 부문, 전략

제33장 부록

영문목차

Yervoy is a prescription medication containing ipilimumab, a monoclonal antibody used in the treatment of certain cancers by enhancing the body's immune system to target cancer cells. It functions by blocking the CTLA-4 (cytotoxic T-lymphocyte antigen 4) receptor on T-cells, a protein that normally suppresses the immune response.

The main forms of Yervoy are 40 mg and 10 mg. The Yervoy 40 mg dose refers to a specific concentration of ipilimumab used in immunotherapy, administered to stimulate the immune system by inhibiting CTLA-4, thereby improving the body's ability to attack and destroy cancer cells. It is prescribed for conditions such as metastatic melanoma and other cancers. Its indications include melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal cancer (CRC). Yervoy is distributed through hospitals, oncology clinics, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.

Tariffs have influenced the yervoy market by increasing costs related to biologic drug production and cold chain logistics. These impacts are felt most strongly in oncology hospitals across north america, europe, and asia pacific. Higher import duties have added pressure to immunotherapy pricing structures. Distribution efficiency has also been affected by customs compliance requirements. At the same time, tariffs are supporting domestic biologics manufacturing and strengthening regional oncology supply chains.

The yervoy market research report is one of a series of new reports from The Business Research Company that provides yervoy market statistics, including yervoy industry global market size, regional shares, competitors with a yervoy market share, detailed yervoy market segments, market trends and opportunities, and any further data you may need to thrive in the yervoy industry. This yervoy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The yervoy market size has grown rapidly in recent years. It will grow from $6.01 million in 2025 to $6.66 million in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to approval for melanoma and solid tumors, success of ctla-4 inhibition, oncology center adoption, unmet needs in advanced cancers, improved survival outcomes.

The yervoy market size is expected to see rapid growth in the next few years. It will grow to $9.93 million in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of immunotherapy pipelines, growth of combination regimens, increasing cancer prevalence, rising oncology investments, improved immune profiling. Major trends in the forecast period include growth of immune checkpoint inhibitors, expansion of combination immunotherapy, rising use in advanced oncology, hospital based immuno oncology care, focus on long term cancer survival.

The rising incidence of melanoma is expected to drive the growth of the Yervoy market in the coming years. Melanoma is a type of skin cancer that develops in melanocytes, the cells responsible for producing melanin, which gives skin its color. The increase in melanoma cases is attributed to greater sun exposure, lifestyle changes, and UV radiation resulting from ozone depletion. Enhanced awareness and improved diagnostic techniques have also contributed to more cases being detected. Yervoy, by targeting the CTLA-4 protein to enhance the immune system's ability to recognize and attack cancer cells, has shown significant benefits for melanoma patients, offering improved survival rates and durable responses even in advanced stages. For example, in January 2024, the American Cancer Society reported that approximately 100,640 new melanoma cases are expected in the United States in 2024, with 59,170 cases in men and 41,470 in women. The organization also estimates that 8,290 people will die from melanoma in 2024, including 5,430 men and 2,860 women. Consequently, the rising incidence of melanoma is supporting growth in the Yervoy market.

Leading companies in the Yervoy market are focusing on developing innovative combination therapies, such as pairing Opdivo (nivolumab) with Yervoy (ipilimumab), to improve treatment efficacy and expand indications across various cancers. This combination works synergistically by targeting complementary immune checkpoint pathways, enhancing the immune response and effectiveness in cancers such as melanoma and renal cell carcinoma. For example, in June 2024, Bristol Myers Squibb, a U.S.-based pharmaceutical company, announced promising results from the CheckMate-9DW trial, which evaluated the combination of Opdivo and Yervoy as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The trial showed that the dual immunotherapy regimen significantly improved overall survival compared to standard treatments with lenvatinib or sorafenib, demonstrating statistically significant benefits for patients with advanced HCC.

In September 2024, Ono Pharmaceutical, a Japan-based company, partnered with Bristol-Myers Squibb KK (BMS KK) to expand the use of Opdivo and Yervoy in treating unresectable advanced or recurrent microsatellite instability-high (MSI-H) colorectal cancer. This collaboration aims to strengthen Ono's immuno-oncology portfolio and address unmet medical needs in cancer treatment. Bristol-Myers Squibb is a Japan-based company that manufactures and markets Yervoy.

Major companies operating in the yervoy market are Bristol-Myers Squibb, Merck & Co., Ono Pharmaceutical

North America was the largest region in the yervoy market in 2025. The regions covered in the yervoy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the yervoy market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The yervoy market consists of sales of ipilimumab and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Yervoy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses yervoy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for yervoy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The yervoy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: 40 ml; 10 ml
• 2) By Clinical Indication: Melanoma; Non-Small Cell Lung Cancer (NSCLC); Renal Cell Carcinoma (RCC); Colorectal Cancer (CRC)
• 3) By Distribution Channel: Hospitals; Oncology Clinics; Retail Pharmacies; Online Pharmacies
• 4) By End User: Adult; Geriatric
• Companies Mentioned: Bristol-Myers Squibb; Merck & Co.; Ono Pharmaceutical
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Yervoy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Yervoy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Yervoy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Yervoy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Growth Of Immune Checkpoint Inhibitors
  • 4.2.2 Expansion Of Combination Immunotherapy
  • 4.2.3 Rising Use In Advanced Oncology
  • 4.2.4 Hospital Based Immuno Oncology Care
  • 4.2.5 Focus On Long Term Cancer Survival

5. Yervoy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Academic Medical Centers
• 5.5 Specialty Oncology Institutes

6. Yervoy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Yervoy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Yervoy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Yervoy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Yervoy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Yervoy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Yervoy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Yervoy Market Segmentation

• 9.1. Global Yervoy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 40 ml, 10 ml
• 9.2. Global Yervoy Market, Segmentation By Clinical Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Melanoma, Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Colorectal Cancer (CRC)
• 9.3. Global Yervoy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Oncology Clinics, Retail Pharmacies, Online Pharmacies
• 9.4. Global Yervoy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adult, Geriatric

10. Yervoy Market Regional And Country Analysis

• 10.1. Global Yervoy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Yervoy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Yervoy Market

• 11.1. Asia-Pacific Yervoy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Yervoy Market

• 12.1. China Yervoy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Yervoy Market

• 13.1. India Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Yervoy Market

• 14.1. Japan Yervoy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Yervoy Market

• 15.1. Australia Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Yervoy Market

• 16.1. South Korea Yervoy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 16.2. South Korea Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Yervoy Market

• 17.1. Western Europe Yervoy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. Western Europe Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Yervoy Market

• 18.1. UK Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Yervoy Market

• 19.1. Germany Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Yervoy Market

• 20.1. France Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Yervoy Market

• 21.1. Eastern Europe Yervoy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 21.2. Eastern Europe Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Yervoy Market

• 22.1. North America Yervoy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 22.2. North America Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Yervoy Market

• 23.1. USA Yervoy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 23.2. USA Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Yervoy Market

• 24.1. Canada Yervoy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 24.2. Canada Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Yervoy Market

• 25.1. South America Yervoy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 25.2. South America Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Yervoy Market

• 26.1. Middle East Yervoy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Middle East Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Yervoy Market

• 27.1. Africa Yervoy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 27.2. Africa Yervoy Market, Segmentation By Type, Segmentation By Clinical Indication, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Yervoy Market Regulatory and Investment Landscape

29. Yervoy Market Competitive Landscape And Company Profiles

• 29.1. Yervoy Market Competitive Landscape And Market Share 2024
  • 29.1.1. Top 10 Companies (Ranked by revenue/share)
• 29.2. Yervoy Market - Company Scoring Matrix
  • 29.2.1. Market Revenues
  • 29.2.2. Product Innovation Score
  • 29.2.3. Brand Recognition
• 29.3. Yervoy Market Company Profiles
  • 29.3.1. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 29.3.2. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 29.3.3. Ono Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

30. Global Yervoy Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Yervoy Market

32. Yervoy Market High Potential Countries, Segments and Strategies

• 32.1 Yervoy Market In 2030 - Countries Offering Most New Opportunities
• 32.2 Yervoy Market In 2030 - Segments Offering Most New Opportunities
• 32.3 Yervoy Market In 2030 - Growth Strategies
  • 32.3.1 Market Trend Based Strategies
  • 32.3.2 Competitor Strategies

33. Appendix

• 33.1. Abbreviations
• 33.2. Currencies
• 33.3. Historic And Forecast Inflation Rates
• 33.4. Research Inquiries
• 33.5. The Business Research Company
• 33.6. Copyright And Disclaimer